Depression Common Among Patients With a Myeloproliferative Neoplasm
Using validated tools, investigators determined that patients with a MPN were likely to experience significant symptoms of depression.
Multiple Myeloma News
MULTIPLE MYELOMA ADVISOR
Multiple Myeloma News
Anticipatory Management, Adherence Strategies Optimize MM Treatment With Selinexor
Commonly reported AEs of selinexor include nausea, anorexia, fatigue, thrombocytopenia, and hyponatremia.
A Look at DARZALEX® (daratumumab) Treatment Regimen in Newly Diagnosed Multiple Myeloma Patients Who are Transplant Eligible
DARZALEX® is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma.
Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Comparison of Triplet vs Doublet Regimen for the Treatment of Plasma Cell Myeloma in Older Patients
An analysis of outcomes for older patients with plasma cell myeloma suggests lenalidomide with bortezomib and dexamethasone is superior to doublet regimens.
VTE Risk Remains High in Newly Diagnosed Multiple Myeloma Despite Thromboprophylaxis
Immunomodulatory imide drug (IMiD) therapy, including thalidomide and lenalidomide, has been associated with a high risk of VTE in patients with NDMM.
Daratumumab for Multiple Myeloma With High-Risk Cytogenetic Factors
The inclusion of daratumumab in multiple myeloma regimens may be linked to better progression-free survival.
Similar Outcomes in VRd and KRd in Multiple Myeloma
VRd is a frequently used regimen in patients with newly diagnosed MM.
Elotuzumab, Lenalidomide-Dexamethasone Combo Improved OS in RRMM
The triplet regimen resulted in an 18% reduction in risk for death.
Prevalence of Iron Toxicity in Lower-Risk Myelodysplastic Syndromes
Researchers aimed to determine iron and oxidative stress characteristics and their effects on survival in patients with lower-risk myelodysplastic syndrome.
Quercetin May Induce Autophagy in Myelodysplastic Bone Marrow, Mouse Model Suggests
A study with murine models suggests that quercetin may induce autophagy in myelodysplastic bone marrow among patients with myelodysplastic syndrome.
Low Enrollment and Reporting of Racial Minorities in Multiple Myeloma Trials
Multiple myeloma trials appear to underrepresent racial minorities in enrollment and in reporting, with no obvious improvement in recent years.
Effects of 5-Azacitidine Dose Changes With Myelodysplastic Syndrome
For patients with myelodysplastic syndrome, 5-azacitidine treatment delays showed some links to outcomes, while dose reductions had less impact.
Diagnosis, Risk-Stratification, Management Updates in Myelodysplastic Syndromes
An overview of the diagnosis and management of MDS, including recent treatment, was discussed in a paper published in the American Journal of Hematology.
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
BCMA-Directed CAR T Cell Therapy Gets Priority Review for Multiple Myeloma
The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study.
Rapid Third-Infusion Protocol of Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma
An observational study determined that 90-minute rapid infusions of daratumumab for RRMM was safe and well-tolerated.
Multiple Myeloma: More Real-World Data Needed To Confirm Effectiveness of New Treatments
More data is needed to determine whether newer treatments are truly improving outcomes among patients with r/r multiple myeloma.
Outcomes After Daratumumab Addition to Induction Therapy in Newly Diagnosed Multiple Myeloma
Researchers assessed the effects of adding daratumumab to standard frontline induction therapy to treat MM in newly diagnosed, transplant-eligible patients.
Phase 1 Trial Featuring First shRNA-Edited CAR-T Therapy to Begin
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma News
